Literature DB >> 16905589

Soluble fractalkine in the cerebrospinal fluid of patients with neuropsychiatric lupus.

E Sato, N Iikuni, T Yoshio, S Minota, N Kamatani, H Okamoto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16905589      PMCID： PMC1798292          DOI： 10.1136/ard.2005.051276

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  6 in total

1.  Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses.

Authors:  P Fraticelli; M Sironi; G Bianchi; D D'Ambrosio; C Albanesi; A Stoppacciaro; M Chieppa; P Allavena; L Ruco; G Girolomoni; F Sinigaglia; A Vecchi; A Mantovani
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

2.  Interferon-inducible protein 10/CXCL10 is increased in the cerebrospinal fluid of patients with central nervous system lupus.

Authors:  Hiroshi Okamoto; Yasuhiro Katsumata; Katsuji Nishimura; Naoyuki Kamatani
Journal:  Arthritis Rheum       Date:  2004-11

3.  Raised monocyte chemotactic protein-1 (MCP-1)/CCL2 in cerebrospinal fluid of patients with neuropsychiatric lupus.

Authors:  N Iikuni; H Okamoto; T Yoshio; E Sato; S Kamitsuji; T Iwamoto; S Momohara; A Taniguchi; H Yamanaka; S Minota; N Kamatani
Journal:  Ann Rheum Dis       Date:  2006-02       Impact factor: 19.103

4.  Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus.

Authors:  E Svenungsson; M Andersson; L Brundin; R van Vollenhoven; M Khademi; A Tarkowski; D Greitz; M Dahlström; I Lundberg; L Klareskog; T Olsson
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

Review 5.  The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes.

Authors: 
Journal:  Arthritis Rheum       Date:  1999-04

6.  Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement.

Authors:  E Trysberg; H Carlsten; A Tarkowski
Journal:  Lupus       Date:  2000       Impact factor: 2.911
  6 in total
  7 in total

1.  Elevated levels of soluble fractalkine and increased expression of CX3CR1 in neuropsychiatric systemic lupus erythematosus.

Authors:  Ling Guo; Xiaoye Lu; Yuan Wang; Chunde Bao; Shunle Chen
Journal:  Exp Ther Med       Date:  2017-08-02       Impact factor: 2.447

Review 2.  The emergence of ADAM10 as a regulator of lymphocyte development and autoimmunity.

Authors:  David R Gibb; Sheinei J Saleem; Natalia S Chaimowitz; Joel Mathews; Daniel H Conrad
Journal:  Mol Immunol       Date:  2011-01-13       Impact factor: 4.407

Review 3.  Cytokines and chemokines in neuropsychiatric syndromes of systemic lupus erythematosus.

Authors:  Hiroshi Okamoto; Akiko Kobayashi; Hisashi Yamanaka
Journal:  J Biomed Biotechnol       Date:  2010-06-29

4.  CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.

Authors:  Fabrine Sales Massafera Tristão; Márcio Lazzarini; Sabine Martin; Majid Amar; Walter Stühmer; Frank Kirchhoff; Lucas Araújo Caldi Gomes; Laurance Lanfumey; Rui D Prediger; Julia E Sepulveda; Elaine A Del-Bel; Rita Raisman-Vozari
Journal:  Neurotox Res       Date:  2015-09-24       Impact factor: 3.911

5.  Identification of a Novel Serum Proteomic Signature for Primary Sjögren's Syndrome.

Authors:  Guillaume Padern; Claire Duflos; Rosanna Ferreira; Said Assou; Philippe Guilpain; Alexandre Thibault Jacques Maria; Radjiv Goulabchand; Pascale Galea; Maja Jurtela; Christian Jorgensen; Yves-Marie Pers
Journal:  Front Immunol       Date:  2021-02-23       Impact factor: 7.561

6.  Pathological role of fractalkine/CX3CL1 in rheumatic diseases: a unique chemokine with multiple functions.

Authors:  Brian Jones; Alisa E Koch; Salahuddin Ahmed
Journal:  Front Immunol       Date:  2012-01-02       Impact factor: 7.561

Review 7.  Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases.

Authors:  Yoshiya Tanaka; Kana Hoshino-Negishi; Yoshikazu Kuboi; Fumitoshi Tago; Nobuyuki Yasuda; Toshio Imai
Journal:  Immunotargets Ther       Date:  2020-11-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.